How to Value a Pulmonology Practice in 2026

Pulmonology practices sit at an interesting intersection in healthcare M&A. They're physician specialty practices with relatively high reimbursement, but they also have significant ancillary revenue opportunities — PFT labs, sleep studies, DME, and chronic care management — that can make a well-built pulmonary practice substantially more valuable than its clinical revenue alone would suggest.

I've worked on pulmonology transactions ranging from solo practitioners joining hospital systems to multi-site pulmonary/sleep medicine groups attracting PE-backed platforms. The valuation dynamics differ meaningfully from general internal medicine or even other medical subspecialties. Here's what actually drives the numbers.

What Pulmonology Practices Sell For

Pulmonology practices typically trade at 4-8x EBITDA, with the range driven primarily by the depth of ancillary revenue streams and the practice's chronic disease patient panel. Revenue multiples generally land at 0.8-1.5x, depending on the payer mix and how much revenue comes from in-house services versus professional fees alone.

At the low end (4-5x EBITDA), you're looking at practices that are essentially clinical-only — the physician sees patients, orders studies at the hospital, and collects professional fees. At the high end (7-8x EBITDA), you'll find practices that have built an integrated pulmonary services business: in-house PFT lab, accredited sleep center, chronic care management programs, and sometimes an oxygen/DME arm. The ancillary revenue transforms the practice from a physician income stream into a platform with multiple profit centers.

Solo pulmonologists selling to hospital systems or larger groups may also see offers structured as employment guarantees — a base salary of $400,000-$550,000 with wRVU-based productivity bonuses — rather than traditional practice acquisitions. In those cases, the "valuation" is really a recruitment package with a nominal asset purchase.

PFT Lab Revenue: The Core Ancillary

A pulmonary function testing lab is the single most important ancillary revenue stream for a pulmonology practice, and its presence (or absence) has an outsized impact on valuation.

In-house PFT testing — spirometry, lung volumes, DLCO, methacholine challenge, cardiopulmonary exercise testing — generates technical component revenue on top of the professional interpretation fee. For a busy practice seeing 80-120 patients per week, the PFT lab can contribute $300,000-$600,000 in annual technical revenue at margins of 60-70% once the equipment is paid for.

Buyers scrutinize PFT lab metrics closely. They want to see utilization rates (what percentage of practice patients get PFTs done in-house versus at the hospital), equipment age (PFT systems have a useful life of 7-10 years, and a body plethysmograph costs $80,000-$120,000 to replace), and compliance with ATS technical standards. A practice that captures 80%+ of its own PFT studies in-house is significantly more valuable than one that sends patients to the hospital for testing.

The PFT lab also functions as a referral retention tool. Primary care physicians send patients for PFTs, and those patients naturally flow into the practice for follow-up. Without an in-house lab, that referral loop is weaker.

Sleep Study Integration

Pulmonology and sleep medicine have natural clinical overlap — many pulmonologists are dual-boarded — and an integrated sleep program can be a major value multiplier.

The economics of sleep medicine have shifted dramatically in the last decade. In-lab polysomnography (PSG) has largely given way to home sleep testing (HST) for uncomplicated obstructive sleep apnea, which means the capital-intensive sleep lab model has evolved. Today, a well-run sleep program typically combines a small in-lab facility (2-4 beds for complex cases, titration studies, and split-night studies) with a high-volume HST program using devices like the WatchPAT or Nox.

From a valuation perspective, sleep revenue is attractive because it's largely incremental — the patients already exist in your pulmonary panel, and sleep complaints are present in a huge percentage of COPD, asthma, and obesity patients. A practice generating $500,000-$1M+ in sleep revenue (professional fees plus technical fees plus CPAP/BiPAP setup) commands a premium because the buyer is acquiring two revenue streams in one transaction.

The key metric buyers evaluate is CPAP compliance follow-up revenue. Every patient started on CPAP needs 30-day and 90-day follow-up visits, mask fitting, and ongoing management. A practice with 500+ active CPAP patients has a built-in recurring visit stream that's highly predictable.

Chronic Disease Management: The Recurring Revenue Engine

Pulmonology is one of the specialties best positioned for chronic care management (CCM) revenue, and practices that have built CCM programs are commanding higher multiples in 2026.

The reason is straightforward: COPD, asthma, interstitial lung disease, and pulmonary fibrosis are chronic conditions that require ongoing management. A COPD patient isn't a one-visit referral — they're a patient who needs quarterly visits, annual PFTs, periodic imaging, medication management, and pulmonary rehabilitation coordination for years. The average COPD patient generates $2,500-$4,000 in annual revenue to the managing pulmonology practice.

Practices that have implemented structured CCM programs — with dedicated care coordinators billing CPT 99490/99491, remote monitoring of spirometry and oxygen saturation, and proactive outreach to prevent exacerbations — generate meaningful incremental revenue. Medicare pays $42-62 per patient per month for CCM services, and a practice with 300 enrolled CCM patients generates $150,000-$220,000 in annual CCM revenue alone.

From a buyer's perspective, a large chronic disease panel is the closest thing to a subscription business in specialty medicine. The patients aren't going anywhere — COPD doesn't resolve — and the revenue is predictable year over year. Practices with 2,000+ active chronic pulmonary patients consistently trade at the upper end of the EBITDA multiple range.

Oxygen and DME: The Double-Edged Sword

Some pulmonology practices have integrated oxygen and durable medical equipment distribution into their operations. This can be valuable, but the economics are more complicated than they appear.

On the positive side, in-house oxygen and DME (nebulizers, CPAP supplies, portable oxygen concentrators) creates a vertically integrated model where the practice captures revenue at every touchpoint: the clinical visit, the diagnostic testing, the therapy prescription, and the equipment supply. A well-run DME arm can contribute $200,000-$500,000 in annual revenue.

On the negative side, DME carries significant regulatory and reimbursement risk. Medicare competitive bidding has compressed margins on oxygen equipment. DME businesses require separate accreditation (typically through The Joint Commission or ACHC), dedicated compliance staff, and inventory management. And the capital requirements — oxygen concentrators, delivery vehicles, warehouse space — can be substantial.

Buyers view integrated DME differently depending on who they are. A PE-backed platform that already operates DME companies will value it as a synergy. A hospital system or physician group that doesn't do DME may actually discount the practice because they don't want to manage a DME operation and will likely shed it post-acquisition.

What Drives Value Up

• Multi-provider practice. A practice with 2-3 pulmonologists plus APPs (nurse practitioners or physician assistants) is dramatically more valuable than a solo. It demonstrates that the practice can retain physicians, distribute the patient panel, and survive the departure of any single provider.
• In-house PFT lab with high capture rate. Practices that do 80%+ of their PFTs in-house at 70% margins are generating a profit center that directly increases EBITDA — and therefore the purchase price.
• Accredited sleep center. AASM-accredited sleep programs signal quality and enable higher reimbursement rates from commercial payers. The accreditation itself has value as a barrier to entry.
• Large chronic disease panel. 2,000+ active COPD/asthma patients represent years of predictable follow-up revenue. This is the metric that gets PE-backed buyers most excited.
• Hospital relationships without employment. Strong referral relationships and hospital privileges without being hospital-employed means the practice retained its independence — and its margin. Hospital-employed pulmonologists typically generate far less EBITDA per physician.

What Kills Value

• Solo practitioner dependency. A single pulmonologist who IS the practice faces the same problem every solo specialist does: the patient relationships leave when they do. Expect 4-5x EBITDA maximum without a succession plan.
• Medicare-heavy payer mix. Pulmonology skews older (COPD patients are typically 55+), so some Medicare exposure is inevitable. But practices with 70%+ Medicare revenue face reimbursement risk that buyers price in aggressively.
• No ancillary services. A clinical-only practice — professional fees with no PFT lab, no sleep, no CCM — is valued as a physician income stream, not a platform. The multiple reflects this.
• Outdated PFT equipment. A PFT lab running 10-year-old equipment that needs $150,000+ in replacements isn't an asset — it's a capital expenditure obligation the buyer will deduct from their offer.
• Pending RAC or OIG audit exposure. Sleep study and DME billing are both high-scrutiny areas for Medicare auditors. Any pending audits or history of recoupment demands will freeze a buyer's interest immediately.

Preparing a Pulmonology Practice for Sale

If you're 2-3 years from an exit, focus on building the ancillary revenue streams that drive premium multiples. If you don't have an in-house PFT lab, build one — the payback period is typically 18-24 months, and it will add significantly more to your sale price than it costs. If you have sleep medicine capability but haven't formalized a sleep program, invest in AASM accreditation and build out your HST volume.

Implement a CCM program for your chronic disease patients. The revenue is meaningful, but more importantly it demonstrates to buyers that you've built a systematic approach to patient retention and recurring revenue. Hire a care coordinator, enroll your highest-acuity patients, and document the program's impact on both revenue and patient outcomes.

Clean up your coding and billing. Pulmonology has several high-value CPT codes (critical care, complex E&M, PFT interpretation, sleep study interpretation) that are also high-audit-risk codes. Make sure your documentation supports your billing levels. A buyer's due diligence will include a billing audit, and you don't want surprises.

The Bottom Line

Pulmonology practice valuation hinges on whether you've built a clinical-only physician practice or an integrated pulmonary services platform. The 4-8x EBITDA range is wide because the difference between these two models is enormous. A solo pulmonologist collecting professional fees trades for 4-5x. A multi-provider practice with an in-house PFT lab, accredited sleep center, CCM program, and 2,000+ chronic disease patients trades for 7-8x. The ancillary revenue streams aren't just nice to have — they're the primary determinant of where you land in the valuation range.